Abstract
Although early stage disease detection and treatment options for clear cell renal cell cancer (ccRCC) improved in recent years, prognosis of patients with late stage ccRCC remains poor, mostly due to development of tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors resistance followed by disease progression. Cancer stem cells (ccRCC-CSC) model has focused a significant attention in recent years as a potential explanation for the tumor heterogeneity, drug resistance, disease recurrence and metastasis of ccRCC and other cancers. Cancer stem cells have been proposed to be responsible for tumor initiation, repopulation and growth that cause patients to succumb to renal cancer. Precise identification of ccRCC-CSC populations and definition of hierarchy of cells within ccRCC tumor including tumor initiating cells and tumor progenitor cells will facilitate accurate characterization of drug targets and ultimately contribute to more personalized and effective care. This mini-review discusses the potential strategies to inhibit the signaling pathways underlying stemness in an effort to treat renal cancer. Mechanism that could be exploited as a therapeutic target against drug resistant ccRCC-CSCs is summarized.
Keywords: Cancer stem cells, CD105, CD133, clear cell, CXCR4, IL-15, RCC, renal cancer.
Current Signal Transduction Therapy
Title:Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Volume: 8 Issue: 3
Author(s): Anna M. Czarnecka and Cezary Szczylik
Affiliation:
Keywords: Cancer stem cells, CD105, CD133, clear cell, CXCR4, IL-15, RCC, renal cancer.
Abstract: Although early stage disease detection and treatment options for clear cell renal cell cancer (ccRCC) improved in recent years, prognosis of patients with late stage ccRCC remains poor, mostly due to development of tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors resistance followed by disease progression. Cancer stem cells (ccRCC-CSC) model has focused a significant attention in recent years as a potential explanation for the tumor heterogeneity, drug resistance, disease recurrence and metastasis of ccRCC and other cancers. Cancer stem cells have been proposed to be responsible for tumor initiation, repopulation and growth that cause patients to succumb to renal cancer. Precise identification of ccRCC-CSC populations and definition of hierarchy of cells within ccRCC tumor including tumor initiating cells and tumor progenitor cells will facilitate accurate characterization of drug targets and ultimately contribute to more personalized and effective care. This mini-review discusses the potential strategies to inhibit the signaling pathways underlying stemness in an effort to treat renal cancer. Mechanism that could be exploited as a therapeutic target against drug resistant ccRCC-CSCs is summarized.
Export Options
About this article
Cite this article as:
Czarnecka M. Anna and Szczylik Cezary, Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206222251
DOI https://dx.doi.org/10.2174/1574362409666140206222251 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-Induced Hepatic Steatosis in Albino Rats
Current Drug Therapy Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Activation of the RNA-Dependent Protein Kinase (PKR) of Lymphocytes by Regulatory RNAs: Implications for Immunomodulation in HIV Infection
Current HIV Research Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine <i>In-vitro</i> Evaluation of Isatin Derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers Cell Lines: A Review
Anti-Cancer Agents in Medicinal Chemistry EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Reviews on Recent Clinical Trials Self Nanoemulsifying Drug Delivery System of Sorafenib Tosylate: Development and <i>In Vivo</i> Studies
Pharmaceutical Nanotechnology Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Synthetic Nanocarriers for Intracellular Protein Delivery
Current Drug Metabolism Employing Genetic Markers to Improve Diagnosis of Thyroid Tumor Fine Needle Biopsy
Current Genomics Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism